.. Interaction-pharmacocinétique-entre-les-isrs-et-le-tamoxifène, 96 3.1. Impacts biologiques de l'interaction médicamenteuse, p.96

A. T. Pedersen-l, . P. Cronin-fenton-d, . T. Sorenson-h, and . L. Lash-t, No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-Inhibiting Medications

A. N. Beral-v and C. D. , Moderate alcohol intake and cancer incidence in women

. Anonyme, Chirurgie en prévention des cancers du sein. Chez les femmes à risque familial ayant une mutation délétère d'un gène BRCA

. Anonyme, Les cancers du sein chez la femme Une évolution naturelle et un pronostic très variables d'une femme à l'autre

. Anonyme, Les effets indésirables des mammographies de dépistage des cancers du sein

. Anonyme, Torémifène et cancer du sein. Pas d'avantage démontré sur le tamoxifène

B. R. Hickey-m, Therapy for menopausal symptoms during and after treatment for breast cancer: safety considerations

B. D. Loprinzi-c, Q. S. , S. J. Veeder-m, and . R. Egner-j, Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

B. M. Budzar-a and C. J. , Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial, Lancet, vol.359, pp.2131-3139, 2002.

B. M. Budzar-a and C. J. , Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, pp.1802-1810, 2003.

B. F. , R. A. Puntoni-m, A. D. Guglielmini-p, and . Fini-a, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial

B. J. Buzdar-a and N. J. , Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer, pp.2247-2258, 2001.

B. L. Pritchard-k and . Goodwin-p, Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review

B. S. Desta-z and L. L. , Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

M. Chavez-mcgregor and E. S. Onland-moret-n, Postmenopausal Breast Cancer Risk and Cumulative Number of Menstrual Cycles, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.4, pp.799-804, 2005.
DOI : 10.1158/1055-9965.EPI-04-0465

C. J. Buist-d, R. M. Boudreau-d, . Lumley-t, and . S. Weiss-n, Breast cancer recurrence risk in relation to antidepressant use after diagnosis, Breast Cancer Res Treat, vol.112, pp.123-132, 2008.

C. R. and H. E. Gibson-l, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

D. M. Penault-llorca-f, Classification des lésions pré-invasives et des carcinomes in situ : doutes, controverses, proposition de nouvelles classifications, Bull Cancer, vol.91, pp.205-210, 2004.

D. Cremoux, P. Diéras-v, and . F. Poupon-m, Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects, Bull Cancer, vol.91, pp.917-927, 2004.

D. V. Guchelaar-h and N. J. Van-de-velde-c, Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer

C. A. Eliassen, R. B. Willett-w, and . E. Hankinson-s, Adult weight change and risk of postmenopausal breast cancer

F. J. Thomas- and R. A. Katon-w, Major depression after breast cancer: a review of epidemiology and treatment

F. B. Dignam-j and B. J. , Five versus more than five years of tamoxifen for lymph node-negative breast cancer : updated findings from the national Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

G. M. Simmons-c, . Nguyen-h, . Verma-s, and . Clemons-m, A pratical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer, pp.573-578, 2005.

G. M. and K. S. Suman-v, The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen, Breast Cancer Res Treat, vol.101, pp.113-121, 2007.

G. M. and R. J. Suman-v, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

H. N. Stearns-v, F. D. , and H. D. , Drug interactions and pharmacogenomics in the treatment of breast cancer and depression, Am J Psychiatry, vol.165, pp.1251-1255, 2008.

H. M. and S. C. Stuckey-b, Management of menopausal symptoms in patients with breast cancer: an evidence-based approach

H. C. Harter-s, Pharmacokinetics of selective serotonin reuptake inhibitors

H. A. and C. J. Baum-m, of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer, Lancet, vol.365, pp.60-62, 2005.

H. A. , R. J. , A. P. , L. M. Elledge-r, and . Bajetta-e, Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, pp.double-blind

4. , S. S. Gomez-a, and . Rodriguez-antona-c, Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

J. R. , J. W. Gnant-m, . Mittlboeck-m, and T. C. Greil-r, Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, vol.366, pp.455-462, 2005.

J. Y. Desta-z and . Stearns-v, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

J. M. Zuo-h and L. K. , Pharmacological characterization of 4- hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Res Treat, vol.85, pp.151-159, 2004.

K. C. , J. D. Gomes-t, . M. Duong-hua, A. I. Pritcahrd-k, and P. L. , Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

D. Randomized, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen

K. K. and M. T. Sasa-m, Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

K. J. Blamey-r, . Boccardo-f, . Tominaga-t, . Duchateau-l, and . Sylvester-r, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

L. L. Hamon-m, Approche neurobiologique de la dépression : nouvelles données

L. T. Cronin-fentond and . P. Ahern-t, Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

L. T. Pedersen-l and . Cronin-fenton-d, Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram

L. T. Rosenberg-c, Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy

L. K. , W. B. Desta-z, and F. D. Jones-d, Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial

L. D. , N. J. , R. V. Newman-n, . Duggan-d, and . Smith, Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition

L. J. , C. A. Shaughnessy-e, K. Mcmasters, and . J. Edwards-m, Excellent outcomes with adjuvant toremifen or tamoxifen in early stage breast cancer. Cancer, pp.2307-2315, 2010.

L. H. , J. L. Seok-l, and S. L. Jang-i, Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

L. Y. Desta-z and F. D. Skaar-t, Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

L. Y. and L. L. Desta-z, Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

L. C. and F. P. Carpenter-l, Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine

L. C. and S. J. Perez-e, Phase III evaluation of fluoxetine for treatment of hot flashes

M. L. , P. J. Quaresma, G. S. , and O. C. , Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and nonvisceral metastases: combined results from two multicentre trials

M. K. Wurz-g and . W. Degregorio-m, Pharmacokinetics of selective estrogen receptor modulators

N. J. Buzdar-a and . Pollak-m, Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial

N. R. Brenner-m and W. M. , Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy, Breast Cancer Res Treat, vol.112, pp.197-201, 2008.

N. H. Vesco-k and . Haney-e, Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis

P. R. Dirix-l and L. C. , Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

S. W. Goetz-m and . Hammann-u, Association between CP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

S. E. Santoro-v, Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

S. V. Johnson and R. J. , Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

S. V. Slack-r, Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial

T. B. and K. A. Coates-a, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

T. R. Siri-i, Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer, pp.83-91, 2008.

T. L. and H. D. Dores-g, Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma

T. B. and G. A. Fontaine-d, Cancer du sein chez la femme, incidence et mortalité, 2000.

W. P. , E. S. , C. J. Stal-o, . Nordenskjold-b, and . Wingren-s, Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer, Breast Cancer Res, vol.9, p.7, 2007.

W. P. Vainikka-l, . Stal-o, . Nordenskjold-b, R. L. Skoog-l, and . Wingren-s, Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients, Breast Cancer Res, vol.7, pp.284-290, 2005.

W. S. Dale, The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review

W. X. , H. J. Subramaniam-m, . P. Goetz-m, . N. Ingle-j, and . C. Spelsberg-t, The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

X. Y. and S. Y. Yao-l, Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment

D. Cremoux-p, Mode d'action du tamoxifène et résistance au tamoxifène

E. M. Gorins-a, Le sein du normal au pathologique : état de l'art, pp.943-952, 2007.

D. Roquancourt, A. M. Bertheau-p-espie, and . Gorins-a, Histologie du sein Le sein du normal au pathologique : état de l'art, Editions Eska, pp.54-59, 2007.

D. Roquancourt, A. M. Bertheau-p-espie, and . Gorins-a, Tumeurs malignes du sein .Tumeurs rares Le sein du normal au pathologique : état de l'art, Editions Eska, pp.367-377, 2007.

M. T. , B. N. Sein, I. :. Espie, and . Gorins-a, Le sein du normal au pathologique : état de l'art, Editions Eska, pp.565-590, 2007.

W. Sites, eMedicine web-site : http://emedicine.medscape.com/article/283561-overview Mai 2010 [109] Europa Donna France web-site : http://www.europadonna.fr/_cancers_du_sein/page_accueil_cancers_sein, 2000.